Cari Almo Gallman is Assistant General Counsel and Head, Global Commercial Oncology Legal and Compliance, leading the team of commercial and regulatory lawyers for Bristol Myers-Squibb’s Oncology Business Unit. In that capacity, Cari and her team provide advice regarding the strategy and execution of commercial and medical tactics for BMS’s oncology medications in market as well as in development. Cari’s team also provides legal support for BMS’ Worldwide Commercial Operations, including on key commercialization areas such as BMS’s multichannel strategy; Field Force capabilities and training; HCP meetings and Congresses; and Strategy and Operations. In her role supporting multiple parts of BMS, Cari sits on the leadership teams for BMS Oncology R&D, BMS Commercial Oncology, and BMS Worldwide Commercial Operations and serves as a strategic partner directly delivering practical, effective, and innovative legal solutions to support business needs while mitigating and defending against legal risks to enable the delivery of innovative medicines to patients.



Prior to joining BMS, Cari was an associate at Debevoise & Plimpton, LLP in New York City, representing pharmaceutical and health care clients in white collar and regulatory matters in a variety of areas, including potential off-label marketing of products, violations of the Anti-Kickback or Anti-Bribery Statutes or the Foreign Corrupt Practices Act, and good manufacturing issues.



Cari holds a J.D. from Harvard Law School and an A.B. from Princeton University, magna cum laude.